The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Neoadjuvant immunotherapy in MSI-high colorectal cancer
Kristen Ciombor, MD, Vanderbilt Health, Nashville, TN, comments on the potential role of neoadjuvant immunotherapy in patients with microsatellite instability (MSI)-high colorectal cancer. Dostarlimab has proven to be efficacious in MSI-high colorectal cancer, and further studies have suggested immunotherapy to be beneficial in the neoadjuvant setting. However, additional research is required to elucidate the optimal duration of treatment, and who will benefit most. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ
